|Bid||365.34 x 100|
|Ask||469.98 x 200|
|Day's Range||429.55 - 438.44|
|52 Week Range||325.35 - 543.55|
|PE Ratio (TTM)||43.96|
|Earnings Date||Nov 2, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||497.30|
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
Categories: Yahoo FinanceGet free summary analysis Regeneron Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Regeneron Pharmaceuticals, Inc. – Amgen Inc., Alnylam Pharmaceuticals, Inc, Biogen Inc., pSivida Corp., Ophthotech Corp. and Sanofi Sponsored ADR (AMGN-US, ALNY-US, BIIB-US, PSDV-US, OPHT-US and SNY-US) that have ... Read more (Read more...)
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.